GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Cash Flow for Lease Financing

Ultimovacs ASA (OSL:ULTI) Cash Flow for Lease Financing : kr-1.77 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Cash Flow for Lease Financing?

Ultimovacs ASA's Cash Flow for Lease Financing for the three months ended in Dec. 2023 was kr-0.46 Mil. Ultimovacs ASA's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 was kr-1.77 Mil.

Compared with last quarter (kr-0.45 Mil in Sep. 2023 ), Ultimovacs ASA's Cash Flow for Lease Financing remained the same in Dec. 2023 (kr-0.46 Mil).

Ultimovacs ASA Cash Flow for Lease Financing Historical Data

The historical data trend for Ultimovacs ASA's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Cash Flow for Lease Financing Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only -1.32 -1.68 -1.72 -1.80 -1.77

Ultimovacs ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.44 -0.43 -0.44 -0.45 -0.46

Ultimovacs ASA Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultimovacs ASA Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Cash Flow for Lease Financing
Comparable Companies
OSL:NYKD OSL:AZT OSL:HBC OSL:BGBIO OSL:CIRCA OSL:EXTX OSL:TRMED OSL:LYTIX OSL:ABS OSL:PCIB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ULTIo:Sweden 7UM:Germany
Address
Ullernchausseen 64, Oslo, NOR, 0379
Website
https://www.ultimovacs.com
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.